- Home
- HRMY vs CEPU Comparison
HRMY vs CEPU Comparison
Compare HRMY & CEPU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HRMY | CEPU |
|---|---|---|
| Founded | 2017 | 1989 |
| Country | United States | Argentina |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.4B |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HRMY | CEPU |
|---|---|---|
| Price | $40.40 | $16.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $51.33 | $17.50 |
| AVG Volume (30 Days) | ★ 765.2K | 340.0K |
| Earning Date | 11-04-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.44 | N/A |
| EPS | ★ 3.17 | 0.13 |
| Revenue | ★ $825,944,000.00 | $607,552,200.00 |
| Revenue This Year | $23.11 | $16.07 |
| Revenue Next Year | $16.15 | $15.36 |
| P/E Ratio | ★ $12.79 | $13.25 |
| Revenue Growth | ★ 21.13 | N/A |
| 52 Week Low | $25.52 | $7.43 |
| 52 Week High | $40.93 | $18.50 |
Technical Indicators
Market Signals| Indicator | HRMY | CEPU |
|---|---|---|
| Relative Strength Index (RSI) | 80.09 | 57.95 |
| Support Level | $38.12 | $16.35 |
| Resistance Level | $40.00 | $17.17 |
| Average True Range (ATR) | 1.20 | 0.82 |
| MACD | 0.25 | -0.10 |
| Stochastic Oscillator | 100.00 | 53.58 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About CEPU Central Puerto S.A. (each represents ten)
Central Puerto SA is a power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity.. The company derives maximum revenue from Electric Power Generation from conventional sources segment.